First-in-Human Pilot Study for the Evaluation of Digma Medical's Endoscopic Gastrointestinal Ablation Device (EGAD) in the Esophagus
Prospective, open-label, single-arm, early feasibility study (EFS) in 2 Patient cohorts: Cohort A - Dose finding / Dose response study in patients with various etiologies undergoing Esophagectomy and Cohort B - Patients with Barrett's Esophagus (BE) with Low-Grade Dysplasia (LDG) or High-Grade Dysplasia (HGD) without a visible (excisable) lesion. This is a pilot study which plan to enroll up to 5 eligible patients in the First Cohort (A) and up to 15 patients in the Second Cohort (B) of the study.
⁃ Cohort A:
• Male or Female ≥18 years of age at the time of consent.
• Scheduled to undergo esophagectomy for malignant or benign indications .
• Contain enough healthy (or with BE) tissue to be ablated (≥1cm) by for EGAD treatment.
• Capable of providing written informed consent.
⁃ Cohort B:
• Male or Female ≥18 and ≤ 70 years of age at the time of consent.
• Documented diagnosis of Barrett's Esophagus (BE) with LGD or HGD, confirmed by biopsy specimen analysis.
• No visible lesion in the esophagus (suitable for endoscopic resection).
• Scheduled to undergo Endoscopic eradication therapy (EET) procedure of Barrett's Esophagus (BE) with dysplasia.
• BE affected tissue length ≥1 cm and ≤ 5cm (as measured endoscopically).
• Capable of providing written informed consent.
• Willingness and ability to comply with follow-up requirements, including endoscopies and biopsies.
• Ability to tolerate and take oral proton pump inhibitor (PPI) medication.